LENEXA, Kan., Oct. 2, 2024 /PRNewswire/ -- Ambetter from Sunflower Health Plan, a product offered by a Centene Corporation (NYSE: CNC) company, which provides insurance to under-insured and uninsured populations through the federal Health Insurance Marketplace®, will offer a variety of affordable health insurance plans to Kansans in 91 counties in plan year 2025. Open enrollment for the Health Insurance Marketplace for Kansas runs from Nov. 1, 2024, through Jan. 15, 2025. Enroll by Dec. 15 for coverage starting Jan. 1, 2025.
"We believe everyone should have the benefits, tools and coverage they need to take charge of their health," said Michael Stephens, plan president and chief executive officer, Sunflower Health Plan. "Ambetter from Sunflower Health Plan has been equipping Kansans with affordable plans to proactively manage their wellness since 2018."
Ambetter from Sunflower Health Plan offers its members access to quality care, convenient services and valuable rewards. The 2025 benefits and offerings include:
Below is a full list of the 91 counties in which Ambetter from Sunflower Health Plan will be offered in 2025:
Kansas residents interested in learning more about Ambetter from Sunflower Health Plan or enrolling in a health plan during the open enrollment period may visit ambetterhealth.com/en/ks.
About Ambetter from Sunflower Health Plan
Ambetter from Sunflower Health Plan serves under-insured and uninsured populations through the federal Health Insurance Marketplace®. Ambetter from Sunflower Health Plan is underwritten by Celtic Insurance Company, which is a Qualified Health Plan issuer in Kansas. For more information, visit ambetterhealth.com/en/ks. This is a solicitation for insurance. For information on your right to receive an Ambetter from Sunflower Health Plan free of discrimination, or your right to receive language, auditory and/or visual assistance services, please visit ambetterhealth.com/en/ and scroll to the bottom of the page.
Last Trade: | US$60.70 |
Daily Change: | -1.28 -2.07 |
Daily Volume: | 5,650,442 |
Market Cap: | US$30.650B |
February 24, 2025 February 04, 2025 October 30, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load